SureTrader
Home > Boards > US OTC > Medical - Drugs >

Innovation Pharmaceuticals Inc. (IPIX)

IPIX RSS Feed
Add IPIX Price Alert      Hide Sticky   Hide Intro
Moderator: LilKahuna, BooDog, sox040713, Astavakra, scottsmith, ZROYPU
Search This Board: 
Last Post: 4/22/2018 12:26:53 AM - Followers: 747 - Board type: Free - Posts Today: 3

Innovation Pharmaceuticals Inc. (IPIX)

https://www.sec.gov/Archives/edgar/data/1355250/000147793217002710/ctix_8k.htm
 

http://www.ipharminc.com/

 
Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564
Email:  info@ipharminc.com

 
About Innovation Pharmaceuticals Inc.: 

Headquartered in Beverly, Massachusetts, Innovation Pharmaceuticals is a publicly-traded company under the symbol "IPIX".
Innovation Pharmaceuticals is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Innovation Pharmaceuticals believes it has a world-class portfolio of first-in-class lead drug candidates and is now advancing them toward market approval, while actively seeking strategic partnerships. Innovation Pharmaceuticals' psoriasis drug candidate Prurisol completed a Phase 2 trial and Innovation Pharmaceuticals is nearing completion of a Phase 2b study. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Innovation Pharmaceuticals' anti-cancer drug Kevetrin successfully concluded a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Innovation Pharmaceuticals has commenced a Phase 2 study. In the laboratory, Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Innovation Pharmaceuticals is in a Phase 2 clinical trial with its novel compound Brilacidin-OM (a defensin mimetic compound) for the prevention of oral mucositis in patients with head and neck cancer. Interim analysis has shown Brilacidin-OM to have a high potential for prevention of severe oral mucositis. Clinical results are consistent with those seen in an animal model in which the occurrence of severe ulcerative oral mucositis was reduced by more than 94% compared to placebo. Innovation Pharmaceuticals' lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infection, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria ("superbugs"). In an ongoing Phase 2 open label Proof-of-Concept trial, favorable interim results have been observed in the first two cohorts of patients treated with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD).  Innovation Pharmaceuticals has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available at http://www.ipharminc.com.

Management: http://www.cellceutix.com/senior-management/

Ongoing Human Trials:  http://clinicaltrials.gov/ct2/results?term=Cellceutix+Pharmaceuticals&Search=Search
 
Product Pipeline:  http://www.ipharminc.com/therapeutic-areas/

 

PIPELINE: 

FDA DESIGNATIONS:

2017 MILESTONES:



Recent News and Press Releases: 
https://finance.yahoo.com/quote/IPIX?p=IPIX
http://www.ipharminc.com/press-release/

 
SEC Filings (CIK:0001355250): 
https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com

 
Share Structure:  See SEC filing link above for current share structure

 

Cellceutix IP - Patent Filings:

EPO
http://worldwide.espacenet.com/searchResults?PA=Cellceutix&DB=EPODOC&locale=en_EP&ST=advanced&compact=false
WIPO
http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2010135170&recNum=1&docAn=US2010034838&queryString=FP:(Cellceutix)&maxRec=1
USPTO
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=Cellceutix&FIELD1=AS&co1=AND&TERM2=&FIELD2=&d=PG01 


http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,796,275.PN.&OS=PN/8,796,275&RS=PN/8,796,275
 

Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
 
External Links: USPTO, USPTO Assignment, Espacenet

http://www.google.com/patents/US8338454

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=6&f=G&l=50&co1=AND&d=PG01&s1=Cellceutix.AS.&OS=AN/Cellceutix&RS=AN/Cellceutix

 
Investor Relations: 

http://www.ipharminc.com/new-faq/
http://www.ipharminc.com/contact-us-1


Following is a DAILY chart:


 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

SureTrader
IPIX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SureTrader
IPIX News: Current Report Filing (8-k) 04/16/2018 01:18:08 PM
IPIX News: Current Report Filing (8-k) 04/09/2018 03:04:31 PM
IPIX News: Quarterly Report (10-q) 02/07/2018 04:59:15 PM
IPIX News: Amended Statement of Ownership (sc 13g/a) 01/11/2018 04:35:53 PM
IPIX News: Statement of Changes in Beneficial Ownership (4) 12/27/2017 03:08:40 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#225013  Sticky Note $IPIX CORPORATE OVERVIEW AND CATALYSTS BooDog 04/19/18 10:04:45 AM
#224508  Sticky Note Innovation Pharmaceuticals Data from Phase 2 Brilacidin Oral LilKahuna 04/16/18 01:25:07 PM
#224375  Sticky Note IPIX Milestones, Clinical Trials, Recent Articles, Corporate Overview, Patent sox040713 04/15/18 06:17:43 PM
#200091  Sticky Note IPIX Clinical Trial Timelines sox040713 10/14/17 08:13:18 PM
#225565   Don't get me wrong Echo. Over that last nerby 04/22/18 12:26:53 AM
#225564   Echo20, What do you mean by this? Investing in kfcyahoo 04/22/18 12:02:50 AM
#225563   I didn't chuckle this time, I flat busted nerby 04/22/18 12:02:26 AM
#225562   Echo20, To qoute you kfcyahoo 04/21/18 11:34:49 PM
#225561   I chuckled. Jealous much? nerby 04/21/18 11:27:13 PM
#225560   This morning I heard a turkey outside my Echo20 04/21/18 11:13:50 PM
#225559   Any unblinding so far? Echo 20 Echo20 04/21/18 11:08:38 PM
#225558   Where in the Boston area do you reside? kfcyahoo 04/21/18 11:04:21 PM
#225557   IMO, there was a definitive shift in IPIX's FlashingLeather 04/21/18 10:46:50 PM
#225556   Gee it so helpful to have IPIX surrogate To infinity and beyond! 04/21/18 10:44:49 PM
#225555   Not even one good explanation for CEO failure To infinity and beyond! 04/21/18 10:38:25 PM
#225553   biodoc, Not sure what you're responding to. I asked kfcyahoo 04/21/18 10:23:10 PM
#225552   PP I'm taking it that you're emphasizing "planned". frrol 04/21/18 10:21:29 PM
#225551   Yeah we're way over those time averages. The frrol 04/21/18 10:19:02 PM
#225550   Retail investors always need to keep in mind frrol 04/21/18 10:16:39 PM
#225549   biodoc, I like to add this: PlentyParanoid 04/21/18 10:05:29 PM
#225548   Agree, you don't want to compromise a trial, frrol 04/21/18 09:55:34 PM
#225547   The indication for prescribing would be for treatment biodoc 04/21/18 09:53:24 PM
#225546   Data lock means nothing more can be added LilKahuna 04/21/18 09:46:14 PM
#225545   Interesting find. It tells me most patients aren’t sox040713 04/21/18 09:44:24 PM
#225544   Ok bad choice of words. My point is Jhawker 04/21/18 09:42:31 PM
#225543   Oops. Fail on my part. biodoc 04/21/18 09:40:05 PM
#225542   Prurisol https://static1.squarespace.com/static/5715352e20c647639137f992/t/593ef98a9f745684e georgejjl 04/21/18 09:36:46 PM
#225541   woody932 you are correct. MY screw up. Should JTORENCE 04/21/18 09:29:11 PM
#225540   Sox, Great post. kfcyahoo 04/21/18 09:22:51 PM
#225539   I believe he was referencing the AveXis SP woody932 04/21/18 09:17:54 PM
#225538   B-UP Due Diligence sox040713 04/21/18 09:16:40 PM
#225537   Yes everyone must be very stupid. scottsmith 04/21/18 09:14:31 PM
#225536   B-OM Due Diligence sox040713 04/21/18 09:13:29 PM
#225535   IPIX reported results in early January, so data Scottwny 04/21/18 09:09:47 PM
#225534   Daubers where did you get that number. The JTORENCE 04/21/18 08:59:36 PM
#225533   Scottwny, it sure seems like it wouldn't be biodoc 04/21/18 08:53:42 PM
#225532   PP, I believe Leo indicated slower than expected biodoc 04/21/18 08:46:34 PM
#225531   Why do you think it took 3 months Scottwny 04/21/18 08:35:51 PM
#225530   Ffrol, I think this may ease your worries PlentyParanoid 04/21/18 08:27:18 PM
#225529   SS you need to review the 4/16/2018 OM farrell90 04/21/18 08:22:11 PM
#225528   IPIX Clinical Trial Summaries sox040713 04/21/18 08:16:51 PM
#225525   CanesNH, Excellent response. kfcyahoo 04/21/18 07:36:30 PM
#225524   CanesNH, you're making an important point that I've biodoc 04/21/18 07:13:21 PM
#225523   They were very good results. As were scottsmith 04/21/18 07:04:19 PM
#225522   Is that the study not registered with clinicaltrials.gov? kfcyahoo 04/21/18 06:45:00 PM
#225521   We will test the resolve of IPIX if tryz 04/21/18 05:58:51 PM
#225520   Holy Cow!!! MC Yogurt is here! IPIX future Barron4664 04/21/18 05:57:31 PM
#225519   Toxicology for oral formulation. Imagine erasing cancer through BooDog 04/21/18 05:52:50 PM
#225518   That IPIX asked for multiple questionnaires in the CanesNH 04/21/18 05:33:34 PM
#225517   A daily occurrence. Williamsc 04/21/18 04:39:20 PM
#225515   With 199 total subjects enrolled in the Prurisol georgejjl 04/21/18 03:57:01 PM
#225514   That company was already valued at $2 to TheDane 04/21/18 03:44:55 PM
#225513   Scottsmith Written without information. Wait for the trial results before pos Echo20 04/21/18 03:37:17 PM
#225512   Pictures speak a 1,000 words look back at CanesNH 04/21/18 03:14:15 PM
PostSubject